House Dust Mite Allergy Drugs Market Report 2024 (Global Edition)

Global House Dust Mite Allergy Drugs Market Report 2024 Market Size Split by Treatment (Antihistamine, Immunotherapy, Other), by Type (Prescription based drugs, Over the counter drugs), by Route of ad...

House Dust Mite Allergy Drugs Market Report Description

We have various report editions of House Dust Mite Allergy Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

House Dust Mite Allergy Drugs Market Insights Video

Competitive Landscape of the House Dust Mite Allergy Drug Market

The competitive context of the house dust mite allergy drug industry offers information broken down by competition. In-depth information is provided about the business's background, finances, earnings, prospective markets, R&D spending, emerging market efforts, international manufacturing locations and infrastructure, manufacturing capabilities, company advantages and disadvantages, introduction of products, goods length and dimension, and sector superiority. The earlier statistics only pertain to the companies' concentration on the house dust mite allergy drug industry.

In May 2024, GSK plc (LSE/NYSE: GSK) reported encouraging breakthrough outcomes for the small molecule seasonal illnesses vaccine program's second stage of investigation (NCT06431607). The trial examined a variety of mRNA compounds in both younger and older persons to assess vaccine candidates that might enhance immunity against the two influenza infections in comparison to the present protocol of services. (Source: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme/) In October 2024, Sanofi and Orano Med, a division of the Orano Organization and a leader in the advancement of specific alpha therapies in chemotherapy, partnered to pool their knowledge in the battle against uncommon tumors and create next-generation radioligand drugs even more quickly. (Source: https://www.sanofi.com/en/media-room/press-releases/2024/2024-10-17-05-30-00-2964590) In October 2024, Merck (NYSE: MRK) and Gilead Sciences, Inc. (Nasdaq: GILD) revealed the findings of the second section research program assessing a mixture of lenacapavir, a first-in-class HIV-1 infection capstone preventive, and islatravir, an investigational amino acid transcription migration drug. (Source: https://www.merck.com/news/gilead-and-merck-announce-phase-2-data-showing-a-treatment-switch-to-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-in-adults-at-wee/)

Top Companies Market Share in House Dust Mite Allergy Drugs Industry: (In no particular order of Rank)

• Shionogi & Co.
• Ltd
• Stallergenes Greer
• Merck & Co.
• Inc
• Torii Pharmaceutical Co.
• Ltd
• Ergomed plc
• Allergy Therapeutics
• DMS Imaging
• HAL Allergy B.V
• Trio Lifescience Private Limited
• Teva Pharmaceutical Industries Ltd
• ICB PHARMA
• Bayer AG
• Sanofi
• Catalent
• Inc
• GSK Plc.
• Merz Pharma
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the House Dust Mite Allergy Drug Market

Which Region Dominates the House Dust Mite Allergy Drug Market in 2024?

According to Cognitive Market Research, North America currently dominates the house dust mite allergy drug market, and the region is expected to have significant growth during the projected period. This is because of common technological advancements, increased research and development, and increasing healthcare expenses. Furthermore, the industry is expected to develop due to the increased demand for particular drugs and the general incidence of cancer in North America.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR) because of the increase in health disorders' prevalence brought on by home dust mite allergies, a growing recognition of the need to distribute understanding of allergens, the rise of medical expenditures, and the growing use of immunology medications to treat house dust mite allergies..

The current report Scope analyzes House Dust Mite Allergy Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America House Dust Mite Allergy Drugs

According to Cognitive Market Research, the global house dust mite allergy drug market size was estimated at USD 1834.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 733.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the house dust mite allergy drug market with a market size of USD 578.97 million in 2024 and is projected to grow at a CAGR of 12.2% during the forecast period. The U.S. market's Stringent governmental regulations.
• The Canada house dust mite allergy drug market had a market share of USD 88.06 million in 2024 and is projected to grow at a CAGR of 13.2% during the forecast period. Canada’s rising awareness among the population.
• The Mexico house dust mite allergy drug market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 66.78 million in 2024.

Europe House Dust Mite Allergy Drugs

According to Cognitive Market Research, the global house dust mite allergy drug market size was estimated at USD 1834.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 550.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

• The United Kingdom house dust mite allergy drug market had a market share of USD 92.46 million in 2024 and is projected to grow at a CAGR of 13.5% during the forecast period. In the UK, house dust mite allergy drug sales witness an upswing due to the nation's rising demand for innovative technology.
• The France house dust mite allergy drug market is projected to witness growth at a CAGR of 11.9% during the forecast period, with a market size of USD 50.63 million in 2024.
• According to Cognitive Market Research, the German house dust mite allergy drug market size was valued at USD 108.97 million in 2024 and is projected to grow at a CAGR of 12.9% during the forecast period. In Germany, house dust mite allergy drug surged due to the presence of major market players.
• The Italy house dust mite allergy drug market is projected to witness growth at a CAGR of 12.1% during the forecast period, with a market size of USD 47.33 million in 2024.
• The Russia house dust mite allergy drug market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 85.30 million in 2024.
• The Spain house dust mite allergy drug market is projected to witness growth at a CAGR of 11.8% during the forecast period with a market size of USD 45.13 million in 2024
• The Luxembourg house dust mite allergy drug market is projected to witness growth at a CAGR of 12.8% during the forecast period, with a market size of USD 17.06 million in 2024.
• The Portugal house dust mite allergy drug market is projected to witness growth at a CAGR of 12.5% during the forecast period, with a market size of USD 11.56 million in 2024.
• The Greece house dust mite allergy drug market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 6.60 million in 2024.
• The Rest of Europe's house dust mite allergy drug market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD 85.30 million in 2024.

Asia Pacific House Dust Mite Allergy Drugs

According to Cognitive Market Research, the global house dust mite allergy drug market size was estimated at USD 1834.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 421.94 million in 2024 and will grow at a compound annual growth rate (CAGR) of 16.2% from 2024 to 2031.

• According to Cognitive Market Research, the China house dust mite allergy drug market size was valued at USD 189.87 million in 2024 and is projected to grow at a CAGR of 15.7% during the forecast period. House dust mite allergy drug surged in China due to Increased focus of the manufacturers and major market players.
• The Japan house dust mite allergy drug market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 58.23 million in 2024.
• The India house dust mite allergy drug market had a market share of USD 50.63 million in 2024 and is projected to grow at a CAGR of 18.0% during the forecast period. India's rising awareness among the populations.
• The South Korean house dust mite allergy drug market is projected to witness growth at a CAGR of 15.3% during the forecast period, with a market size of USD 42.19 million in 2024.
• The Australian house dust mite allergy drug market is projected to witness growth at a CAGR of 15.9% during the forecast period, with a market size of USD 21.94 million in 2024.
• The South East Asia house dust mite allergy drug market is projected to witness growth at a CAGR of 17.2% during the forecast period, with a market size of USD 29.11 million in 2024.
• The Rest of Asia Pacific house dust mite allergy drug market is projected to witness growth at a CAGR of 16.0% during the forecast period, with a market size of USD 29.96 million in 2024.

South America House Dust Mite Allergy Drugs

According to Cognitive Market Research, the global house dust mite allergy drug market size was estimated at USD 1834.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 91.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil house dust mite allergy drug market size was valued at USD 39.26 million in 2024 and is projected to grow at a CAGR of 14.2% during the forecast period. House dust mite allergy drug flourished in Brazil due to increasing demand for packaged food and beverages.
• Argentina's house dust mite allergy drug market had a market share of USD 15.41 million in 2024 and is projected to grow at a CAGR of 14.5% during the forecast period. Argentina's rising personal disposable income .
• Colombia house dust mite allergy drug market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 8.16 million in 2024.
• Peru house dust mite allergy drug market is projected to witness growth at a CAGR of 13.8% during the forecast period, with a market size of USD 7.52 million in 2024.
• Chile house dust mite allergy drug market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 6.60 million in 2024.
• The Rest of Latin America's house dust mite allergy drug market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 14.77 million in 2024.

Middle East and Africa House Dust Mite Allergy Drugs

According to Cognitive Market Research, the global house dust mite allergy drug market size was estimated at USD 1834.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 36.69 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2031..

• The GCC Countries house dust mite allergy drug market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 15.70 million in 2024. House dust mite allergy drug sales flourish due to the presence of major market players.
• The Egypt house dust mite allergy drug market is projected to witness growth at a CAGR of 14.2% during the forecast period, with a market size of USD 3.85 million in 2024.
• The South Africa house dust mite allergy drug market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 5.80 million in 2024. House dust mite allergy drug sales flourished in South Africa due to increasing demand and regulatory support.
• The Turkey house dust mite allergy drug market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 3.16 million in 2024.
• The Nigeria house dust mite allergy drug market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 3.85 million in 2024.
• The Rest of the MEA house dust mite allergy drug market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 4.33 million in 2024.

House Dust Mite Allergy Drugs Market Analysis

House Dust Mite Allergy Drug Market Treatment Segment Analysis

According to Cognitive Market Research, antihistamines are likely to dominate the house dust mite allergy drug market over the forecast period. The increase can be attributed to the rise in sales of antihistamines. Antihistamines are medications commonly used to treat signs of allergies, including congestion, itching, concussion, and reactivity to wounds or bites from insects. They are additionally useful as a short-term treatment for drowsiness to alleviate vomiting or feeling sick and to avoid mobility illness.

Immunotherapy is the fastest-growing segment in the house dust mite allergy drug market. Because of improvements in drug R&D efforts and the rise in important businesses. For specific cancer individuals, immunotherapy can be a game-changer, producing significant and long-lasting results. Immunotherapy may occasionally even result in the total eradication of malignancies.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of House Dust Mite Allergy Drugs Industry. Request a Free Sample PDF!

House Dust Mite Allergy Drug Market Type Segment Analysis

According to Cognitive Market Research, the prescription-based drugs segment holds the largest market share. This is because of the rise in the incidence of allergies caused by house dust mites and the efforts made by both public and private organizations to raise awareness of these conditions.

In the house dust mite allergy drug market, the rapidly growing sector is the over-the-counter drugs. Over-the-counter medications are easily accessible, these treatments are affordable, and both the medication and the substance are very successful in treating vertigo issues. Many over-the-counter drugs are used to treat allergies, such as asthma, itching, and insect stings or assaults.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

House Dust Mite Allergy Drugs Route of administration Segment Analysis

House Dust Mite Allergy Drug Market Route of administration Segment Analysis

According to Cognitive Market Research, the nasal administration segment holds the largest market share. This is because of improvements in pharmacological R&D efforts and increasing demand for nasal administration. When quick medicine delivery is required in a disaster, nasal administration can be helpful. It is a simple method that doesn't call for specialized personnel or anesthesia.

In the house dust mite allergy drug market, the rapidly growing sector is oral medication. Oral medication methods are an especially widely used and practical way to take medicine. They have benefits, including non-invasiveness, acceptance by patients, and simplicity of usage. Tablets, pills, drinks, and other preparations that are ingested and distributed via the digestive process are examples of oral drug techniques.

• Oral medication
• Nasal administration

House Dust Mite Allergy Drugs Distribution Channel Segment Analysis

House Dust Mite Allergy Drug Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the hospital pharmacy segment holds the largest market share. This is because of the increase in the number of people who have allergic disorders, the rise of interest in antibody therapies, and the federal government's efforts to improve hospital pharmacies.

In the house dust mite allergy drug market, the rapidly growing sector is the retail pharmacy. Because retail stores offer quick accessibility to goods and personalized support. They provide medical supplies and prescription drugs to the general public as well as medical professionals. They also have a large range of personal hygiene products, art supplies, imaging gear, and wildlife supplies.

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion